Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 46 Published: March 31, 2022 Report Code: GMDGDHC22056TDB

Leukotriene A4 hydrolase (LTA4H) is an enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTB4 is a potent lipid chemoattractant involved in inflammation, immune responses, host defense against infection and PAF-induced shock.

The LTA4H – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for LTA4H, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for LTA4H and features dormant and discontinued projects.

Key Therapy Areas in the LTA4H Pipeline Drugs Market

The key therapy areas in the LTA4H pipeline drugs market are Respiratory, Immunology, Cardiovascular, Dermatology, and Hematological Disorders.

LTA4H Pipeline Drugs Market, by Therapy Areas

LTA4H Pipeline Drugs Market, by Therapy Areas

For more target insights, download a free report sample

Key MoA in the LTA4H Pipeline Drugs Market

The key mechanism of action in the LTA4H pipeline drugs market is Leukotriene A 4 Hydrolase Inhibitor.

LTA4H Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the LTA4H pipeline drugs market are Oral, Inhalational and Topical.

LTA4H Pipeline Drugs Market Analysis, by RoA

LTA4H Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the LTA4H Pipeline Drugs Market

The key molecule type in the LTA4H pipeline drugs market is Small Molecule.

Major Companies in the LTA4H Pipeline Drugs Market

The major companies in the LTA4H pipeline drugs market are Celtaxsys Inc, Covenant Therapeutics LLC, and Naegis Pharmaceuticals Inc.

LTA4H Pipeline Drugs Market, by Major Companies

LTA4H Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

LTA4H Pipeline Drugs Market Overview

Key Therapy Areas Respiratory, Immunology, Cardiovascular, Dermatology, and Hematological Disorders
Key Mechanisms of action Leukotriene A 4 Hydrolase Inhibitor
Key Routes of Administration Oral, Inhalational and Topical
Key molecule types Small Molecule
Major companies Celtaxsys Inc, Covenant Therapeutics LLC, and Naegis Pharmaceuticals Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of LTA4H
  • The pipeline guide reviews pipeline therapeutics for LTA4H by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in LTA4H therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates LTA4H therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for LTA4H

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for LTA4H
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding LTA4H pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Celtaxsys Inc

    Covenant Therapeutics LLC

    Naegis Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Overview

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Companies Involved in Therapeutics Development

Celtaxsys Inc

Covenant Therapeutics LLC

Naegis Pharmaceuticals Inc

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Drug Profiles

acebilustat – Drug Profile

Product Description

Mechanism Of Action

History of Events

CTX-3397 – Drug Profile

Product Description

Mechanism Of Action

CTX-3417 – Drug Profile

Product Description

Mechanism Of Action

EDO-66 – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Leukotriene A4 for Chronic Obstructive Pulmonary Disease – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit LTA4H for Inflammation – Drug Profile

Product Description

Mechanism Of Action

ubenimex – Drug Profile

Product Description

Mechanism Of Action

History of Events

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Dormant Products

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Discontinued Products

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC

3.3.2.6) – Product Development Milestones

Featured News & Press Releases

Oct 22, 2018: Results from Celtaxsys Acebilustat phase 2 trial in cystic fibrosis patients showing clinically meaningful improvement in pulmonary exacerbations presented at the North American Cystic Fibrosis Conference

Oct 16, 2018: Eiger BioPharmaceuticals announces phase 2 ULTRA results of Ubenimex in lower leg lymphedema: study did not meet primary or secondary endpoint

Oct 11, 2018: Data from Celtaxsys Acebilustat phase 2 trial addressing lung inflammation in CF patients to be presented at the North American Cystic Fibrosis Conference

Aug 02, 2018: Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

May 17, 2018: Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

Feb 01, 2018: Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines

Jan 16, 2018: Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint

Jan 04, 2018: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients

May 17, 2017: Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema

May 17, 2017: Celtaxsys Announces Full Enrollment of Its Landmark EMPIRE-CF Phase 2b Clinical Trial Assessing the Potential of Novel Anti-inflammatory Investigational Therapy, Oral Acebilustat, to Preserve Lung Function in CF Patients

May 15, 2017: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

May 04, 2017: Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City

Jan 03, 2017: Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

Nov 03, 2016: Celtaxsys Announces Publication of Clinical Trial Results Demonstrating Novel Anti-inflammatory Medicine, Oral Acebilustat, Reduced Lung Inflammation Without Increased Risk of Immunosuppression, in CF Patients

Oct 28, 2016: Celtaxsys Announces Publication of Results Demonstrating Safety, Tolerability and PK/PD Profile of Novel Anti-inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials including CF Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Celtaxsys Inc, 2022

Pipeline by Covenant Therapeutics LLC, 2022

Pipeline by Naegis Pharmaceuticals Inc, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.